Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALLO allogene.com
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Unlike autologous CAR T therapies that require manufacturing from each patient's own cells, Allogene's off-the-shelf approach uses donor-derived cells to enable on-demand availability and broader scalability. The company's lead oncology candidate, cemacabtagene ansegedleucel (cema-cel), is in a pivotal Phase 2 trial (ALPHA3) as a first-line MRD-guided consolidation therapy in large B-cell lymphoma and has received FDA RMAT and Fast Track designations. In autoimmune disease, ALLO-329 is a next-generation dual-targeting anti-CD19/CD70 AlloCAR T product incorporating proprietary Dagger technology designed to reduce or eliminate conventional chemotherapy-based lymphodepletion; it is being evaluated in the Phase 1 RESOLUTION trial across systemic lupus erythematosus, scleroderma, and inflammatory myositis. The company's AlloCAR T oncology products utilize technologies licensed from Cellectis and Servier, while ALLO-329 uses CRISPR gene-editing technology. Allogene trades on Nasdaq under the ticker ALLO. Updated
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Penny stocks are some of my favorite stocks to watch. When these young budding companies release news, their stock prices can make tremendous moves. Of course, if the news is positive, those…
With the earnings season winding down and windows for making insider purchases opening up, insiders have been scooping up shares of these six stocks.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Monday's top analyst upgrades and downgrades included Accenture, Analog Devices, Baxter International, Best Buy, Coinbase Global, Johnson Controls, Lam Research, Micron Technology and Qualcomm.
Thursday's top analyst upgrades and downgrades included AppLovin, Carvana, CrowdStrike, DocuSign, Fisker, Foot Locker, Intuitive Surgical, Rivian Automotive, Shopify, UnitedHealth, Workday and XPO Logistics.
Friday's additional top analyst upgrades and downgrades included Allogene Therapeutics, CSX, Norfolk Southern, Qualcomm, Toyota and Yelp.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 1.5 million shares of Allogene on December 14.
Friday's top analyst upgrades and downgrades included Caesars Entertainment, Charter Communications, Conagra Brands, Corning, Denny’s, General Electric, Home Depot, Plug Power, Sirius XM, 3M and Union Pacific.
Monday’s top analyst upgrades and downgrades included Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and more.
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease.
The Wall Street consensus 12-month price target for ALLO is $9.00.
